Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H SHEPPARD

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of Medicinal Chemistry|April 1, 1974
Synthesis and antireserpine activity of peptides of L-dopaA M Felix, D P Winter, S S Wang, et al.
ACS Central Science|August 13, 2019
Optically Robust and Biocompatible Mechanosensitive Upconverting NanoparticlesAlice Lay, Olivia H Sheppard, Chris Siefe, et al.
AIDS Research and Human Retroviruses|September 10, 1999
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivorsM R Betts, J F Krowka, T B Kepler, et al.
AIDS (London, England)|September 14, 2000
Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study GroupF Spielberg, C Critchlow, E Vittinghoff, et al.
Journal of Virology|October 29, 1997
Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected ZambiansM R Betts, J Krowka, C Santamaria, et al.
Oncogene|February 29, 2012
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanismsY-N Liu, J J Yin, W Abou-Kheir, et al.
The Journal of Infectious Diseases|March 28, 2003
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine StudyH Cao, P Kaleebu, D Hom, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of Medicinal Chemistry|April 1, 1974
Synthesis and antireserpine activity of peptides of L-dopaA M Felix, D P Winter, S S Wang, et al.
ACS Central Science|August 13, 2019
Optically Robust and Biocompatible Mechanosensitive Upconverting NanoparticlesAlice Lay, Olivia H Sheppard, Chris Siefe, et al.
AIDS Research and Human Retroviruses|September 10, 1999
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivorsM R Betts, J F Krowka, T B Kepler, et al.
AIDS (London, England)|September 14, 2000
Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study GroupF Spielberg, C Critchlow, E Vittinghoff, et al.
Journal of Virology|October 29, 1997
Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected ZambiansM R Betts, J Krowka, C Santamaria, et al.
Oncogene|February 29, 2012
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanismsY-N Liu, J J Yin, W Abou-Kheir, et al.
The Journal of Infectious Diseases|March 28, 2003
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine StudyH Cao, P Kaleebu, D Hom, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Pageof 8